BG4-12732-20664
2 vaccinations
1 coded response
23 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 838 / ID
- Registered
- 2021-06-10
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-06-10
Registered in v-safe
-
2021-06-10
Dose 1 — Pfizer-BioNTech
- 2021-06-10
- 2021-06-13
- 2021-06-14
- 2021-06-15
- 2021-06-16
- 2021-06-17
- 2021-06-24
-
2021-07-01
Dose 2 — Pfizer-BioNTech
- 2021-07-01
- 2021-07-02
- 2021-07-03
- 2021-07-04
- 2021-07-05
- 2021-07-06
- 2021-07-07
- 2021-07-08
- 2021-07-15
- 2021-07-22
- 2021-07-29
- 2021-08-05
- 2021-08-13
-
2021-09-30
Survey response — 3 months, dose 2MedDRA: Ageusia, Anosmia, COVID-19, Cough, Fatigue, Rhinorrhoea — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Currently have COVID-19 - cough, runny nose, loss of taste and smell, fatigueMedDRA releases: 2024-11 · check-in free text available
- 2021-12-30
- 2022-07-01
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-06-10 | Pfizer-BioNTech | |
| 2 | 2021-07-01 | Pfizer-BioNTech | No |
Free text
Release 9 — 3 months, dose 2
Symptoms: Currently have COVID-19 - cough, runny nose, loss of taste and smell, fatigue
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release